Lan Cao Email & Phone Number

Cambridge, Cambridgeshire, Gb

Tokyo, Jp

Lead a newly established, cross-functional integrated "Cell Therapy Innovation" department covering Discovery (including target selection, CAR construct design, comparative immunobiology), Genetical Engineering (e.g., CRISPR multiplexed editing), Cell Platform Development (NK cells, gamma-delta T cells, iPS derived immune cells), and Early-to-Mid stage Product Development (process and analytical).

Tokyo, Jp

-- Oversee the development of cell therapy and ex-vivo gene therapy platforms and products, focusing on the design and continuous optimization of innovative and differentiated autologous and allogeneic cell therapy platforms and products across various therapeutic areas (Oncology, Rare Diseases and Gastrointestinal), including natural killer (NK) cells, induced pluripotent stem cell (iPSc)-derived T cell and NK cells, and gamma delta T cells.--Responsible for the design and development of cutting-edge enabling technologies, including various types of viral vectors, gene and genome-editing tools, such as clustered regularly interspaced short palindromic repeats (CRISPR) approaches and other novel transformative technologies.-- Cell Therapy Translational Engine Leadership Team Member.

Tokyo, Jp

-- Collaborate with MDACC to develop off-the-shelf, allogeneic CAR NK cell therapies, ‘armored’ with IL-15, for the treatment of B-cell malignancies and other cancers.-- Global Program Leader of the iPSC-derived off-the-shelf, allogeneic CAR-T program, in collaboration with Profs. Yamanaka and Kaneko at Kyoto University-- Collaborate with Memorial Sloan Kettering Cancer Center (MSK) to discover and develop novel chimeric antigen receptor T-cell (CAR-T) products for the treatment of multiple myeloma, acute myeloid leukemia and additional solid tumor indications.-- Novel CAR-T products based on the “Prime” (proliferation inducing and migration enhancing) CAR-T platform licensed from Noile-Immune Biotech Inc.-- Multiple Takeda Internal CAR-T products-- Collaborate with Gamma-Delta Therapeutics Ltd to develop tissue- and blood-derived off-the-shelf, allogeneic gamma delta T cell products

Boston, Ma, Us

Development of allogeneic CAR-T cell therapies based on CRISPR/Cas9 gene-editing technology

As the head of CMC, I oversee all the CMC related activities for the three portfolio companies of Battersea Biotech:NKarta Therapeutics (portfolio company), South San Francisco, CA. Genetically modified NK cellsMarker Therapeutics (portfolio company), Houston, TX. Tumor antigen specific T cellsArcellx Inc (portfolio company), Germantown, MD. Next generation CAR-T cells

"Unum" equals one. Formed in 2014, Unum Therapeutics is a Cambridge, Massachusetts-based cellular therapeutics company ushering in a new wave of innovation in cancer immunotherapy. Unum was built to transform cancer treatment through the discovery, development and commercialization of novel antibody-coupled cellular immunotherapies. Unum’s vision: a single cell therapy that can augment the activity of multiple antibodies to treat many different cancers. In my role as Director of Process and Analytical Development, I am responsible for Unum’s development work for both engineered T cells and viral vector production.

Basel, Baselstadt, Ch

--Team lead in late phase Process Development (PD) and Process Characterization (PC) of cellular products based on the Chimeric Antigen Receptor Technology (CAR) platform, such as CAR T cells.--Developed and implemented major process changes in the clinical manufacturing, which significantly increased the process efficiency and manufacturing success rates. --Leading technical support for clinical manufacturing, including troubleshooting and problem-solving. --Supporting global filings (e.g., IND, IMPD and BLA) to regulatory authorities by preparing CMC documentations.

Basel, Baselstadt, Ch

--Supported technology transfer of Chimeric Antigen Receptor Technology (CARs) from UPenn to Novartis--Established the laboratory and the team of CAR T cell late phase process development at Novartis

Canton, Massachusetts, Us

Team lead in developing novel regenerative medicine products (cellular and acellular) for various medical conditions.

Cambridge, Massachusetts, Us

Advisor: Prof. David J. Mooney, Bioengineering, School of Engineering and Applied Sciences.Research focus: Development of cell therapy approaches based on new biomimetic materials to control the cell-cell interactions between mesenchymal stem cells.

Cambridge, Massachusetts, Us

Advisor: Prof. David J. Mooney, Bioengineering, School of Engineering and Applied Sciences.Collaborator: Prof. George L. King, M.D., Chief Scientific Officer, Professor of Medicine, Joslin Diabetes Center, Harvard Medical School.Research focus: Development of new approaches (enhancing the cell sensitivity to protein drugs) to promote new blood vessel formation (angiogenesis) for treating ischemia diseases, especially on diabetics which typically have diminished angiogenic responses.

Seattle, Wa, Us